Renew U Medispa & Laser Center
Renew U Medispa & Laser Center · 22789 Three Notch Road · California, MD 20619
4.8· 25 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
Renew U Medispa & Laser Center is a medical spa in California, Maryland, which its website describes as serving Southern Maryland with laser treatments, injectables and skincare services. The site introduces Dr. Cyril Morfaw, DNP, who it says has more than 24 years of healthcare experience, four of them in aesthetics. On Google the practice has a 4.8-star rating across 25 reviews dating back to 2021, though none were posted in the past year. Reviewers most often mention the provider's knowledge and the staff.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2025-09-08. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.8 across 25 Google reviews. Of the 22 reviews we analyzed, 21 (95%) are positive (4–5★) and 1 (5%) are negative (1–2★).
What patients like
- Knowledgeable, professional providers9 reviews
- Friendly, helpful staff5 reviews
- Feeling listened to5 reviews
- Weight-loss results3 reviews
Common complaints
Very few complaints — only 1 negative review, with no recurring theme.
Most recent Google reviews
Michele C.★★★★★2024-04-25Maureen is stellar! She explains everything on great detail before any procedure is done. Maureen truly cares about her patients and their desired results. I highly recommend her. Mary Sue the Patient Director, is awesome! Outstanding customer service!
Jill C.★★★★★2023-02-11I've been going there for years. Always professional. They always really make me feel cared for and at ease during a procedure and even afterward. They are the only place I trust!
Lawrie B.★★★★★2022-08-25I was pleasantly surprised by my experience with Renew U, Maureen is so sweet and a fantastic injector. She’s very knowledgeable and offered so much more information than any experience I’ve had in the past. You can tell she cares a lot for what she does. I highly recommend Renew U and Maureen.
Erin T.★★★★★2022-03-02Maureen and her staff are amazing! Very professional. They took the time to answer any questions, I never felt rushed. I highly recommend going to see Maureen!
Cynthia (.★★★★★2022-02-20Wonderful skincare. Worth the drive from DC. Very professional staff. You won’t be disappointed.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs